Embecta Corp

NASDAQ EMBC

Data sourced from iex and EODHD
Download Data

Embecta Corp EBIT Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: -32.47%

Embecta Corp EBIT Ratio 1 year YoY Change (%) is -32.47% for the Trailing 12 Months (TTM) ending March 31, 2024, a 6.21% change year over year. EBIT Ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Embecta Corp EBIT Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 25.57%, a -34.63% change year over year.
  • Embecta Corp EBIT Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 39.11%, a -10.73% change year over year.
  • Embecta Corp EBIT Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 43.81%.
NASDAQ: EMBC

Embecta Corp

CEO Mr. Devdatt Kurdikar
IPO Date April 1, 2022
Location United States
Headquarters 300 Kimball Drive, Parsippany, NJ, United States, 07054
Employees 2,200
Sector Healthcare
Industry Medical instruments & supplies
Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

AKYA

Akoya Biosciences Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email